The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding
Open accessAbstract
Background—: Fixed-dose unmonitored treatment with dabigatran etexilate is effective and has a favorable safety profile in the prevention of stroke in atrial fibrillation patients compared with warfarin. We hypothesized that genetic variants could contribute to interindividual variability in blood concentrations of the active metabolite of dabigatran etexilate and influence the safety and efficacy of dabigatran. Methods and Results—: We successfully conducted a genome-wide association study in 2944 Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) participants. The CES1 single-nucleotide polymorphism rs2244613 was associated with trough concentrations, and the ABCB1 single-nucleotide polymorphism rs4148738 and the CES1 single-nucleotide polymorphism rs8192935 were associated with peak concentrations at genome-wide significance (P<9×10−8) with a gene-dose effect. Each minor allele of the CES1 single-nucleotide polymorphism rs2244613 was associated with lower trough concentrations (15% decrease per allele; 95% confidence interval, 10–19;P=1.2×10−8) and a lower risk of any bleeding (odds ratio, 0.67; 95% confidence interval, 0.55–0.82;P=7×10−5) in dabigatran-treated participants, with a consistent but nonsignificant lower risk of major bleeding (odds ratio, 0.66; 95% confidence interval, 0.43–1.01). The interaction between treatment (warfarin versus all dabigatran) and carrier status was statistically significant (P=0.002), with carriers having less bleeding with dabigatran than warfarin (hazard ratio, 0.59; 95% confidence interval, 0.46–0.76;P=5.2×10−5) in contrast to no difference in noncarriers (hazard ratio, 0.96; 95% confidence interval, 0.81–1.14;P=0.65). There was no association with ischemic events, and neither rs4148738 nor rs8192935 was associated with bleeding or ischemic events. Conclusions—: Genome-wide association analysis identified that carriage of the CES1 rs2244613 minor allele occurred in 32.8% of patients in RE-LY and was associated with lower exposure to active dabigatran metabolite. The presence of the polymorphism was associated with a lower risk of bleeding. Clinical Trial Registration—: URL:http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
GCTA: a tool for genome-wide complex trait analysis
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.11.011 · Cited by 8,279
A second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium (2007) · Nature · doi:10.1038/nature06258 · Cited by 4,438
Integrating common and rare genetic variation in diverse human populations
The International HapMap 3 Consortium (2010) · Nature · doi:10.1038/nature09298 · Cited by 3,026
LocusZoom: regional visualization of genome-wide association scan results
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., Boehnke, M., Abecasis, G. R., & Willer, C. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq419 · Cited by 2,707
MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes
Li, Y., Willer, C. J., Ding, J., Scheet, P., & Abecasis, G. R. (2010) · Genetic Epidemiology · doi:10.1002/gepi.20533 · Cited by 1,843
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081 · cited 1×
“daily) versus higher (150 mg twice daily) dose of dabigatran in the overall study.(16) The observed genetic effect was thus”
BackgroundStangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Stangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 722
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Miller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Stangier, J., & Clemens, A. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609343004 · Cited by 337
Ezekowitz, M. D., Connolly, S., Parekh, A., Reilly, P. A., Varrone, J., Wang, S., Oldgren, J., Themeles, E., Wallentin, L., & Yusuf, S. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.02.005 · Cited by 332
Self-citationLIESENFELD, K. ‐., LEHR, T., DANSIRIKUL, C., REILLY, P. A., CONNOLLY, S. J., EZEKOWITZ, M. D., YUSUF, S., WALLENTIN, L., HAERTTER, S., & STAAB, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 305
Self-citationCurrent Progress on Esterases: From Molecular Structure to Function
Satoh, T., Taylor, P., Bosron, W. F., Sanghani, S. P., Hosokawa, M., & Du, B. N. L. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.488 · Cited by 295
Zhu, H.-J., Patrick, K. S., Yuan, H.-J., Wang, J.-S., Donovan, J. L., DeVane, C. L., Malcolm, R., Johnson, J. A., Youngblood, G. L., Sweet, D. H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.04.015 · Cited by 229
Pindel, E. V., Kedishvili, N. Y., Abraham, T. L., Brzezinski, M. R., Zhang, J., Dean, R. A., & Bosron, W. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14769 · Cited by 224
Mendell, J., Kastrissios, H., GREEN, M. L., Carrothers, T. J., Song, S., Patel, I. J., Antman, E. M., Giugliano, R. P., Kunitada, S., Dornseif, B. E., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0566 · Cited by 150
Baker, W. L., & Phung, O. J. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966572 · Cited by 113
Woodahl, E. L., & Ho, R. J. Y. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489108 · Cited by 112
Human carboxylesterase 1: from drug metabolism to drug discovery
Redinbo, M. R., Bencharit, S., & Potter, P. M. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310620 · Cited by 110
Binding and Hydrolysis of Meperidine by Human Liver Carboxylesterase hCE-1
Zhang, J., Burnell, J. C., Dumaual, N. G., & BOSRON, W. F. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34901-8 · Cited by 101
Danks, M. K., Morton, C. L., Krull, E. J., Cheshire, P. J., Richmond, L. B., Naeve, C. W., Pawlik, C. A., Houghton, P. J., & Potter, P. M. (1999) · PubMed · Cited by 96
Geshi, E., Kimura, T., YOSHIMURA, M., Suzuki, H., Koba, S., Sakai, T., Saito, T., Atsuro, K. O. G. A., Muramatsu, M., & Katagiri, T. (2005) · Hypertension Research · doi:10.1291/hypres.28.719 · Cited by 96
Wadkins, R. M., Morton, C. L., Weeks, J. K., Oliver, L., Wierdl, M., Danks, M. K., & Potter, P. M. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.2.355 · Cited by 61
Lehr, T., Schaefer, H.-G., & Staab, A. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833b747f · Cited by 12
Self-citation
Cited by
Human carboxylesterases: a comprehensive review
Wang, D., Zou, L., Jin, Q., Hou, J., Ge, G., & Yang, L. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.005 · Cited by 543
Metadata
- Authors
- Paré, G., Eriksson, N., Lehr, T., Connolly, S., Eikelboom, J., Ezekowitz, M. D., Axelsson, T., Haertter, S., Oldgren, J., Reilly, P., Siegbahn, A., Syvanen, A.-C., Wadelius, C., Wadelius, M., Zimdahl-Gelling, H., Yusuf, S., & Wallentin, L.
- Venue
- Circulation
- Published
- 2013-04-02
- Volume
- 127
- Issue
- 13
- Pages
- 1404-1412
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2122667952
- Cited by
- 255
- References
- 29
- FWCI
- 30.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.